IP Library › Granted Patent US 12,252,553
Granted Patent B2
US 12,252,553 · App. 18/074,151 · Granted Mar 18, 2025

Crystalline salt forms

Inventors: Scott M. Duncan (Bedford, MA); Martin P. Redmon (Boston, MA)
Assignee: Stealth BioTherapeutics Inc.
C07K5/0817A61K38/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,553
App. No.
18/074,151
Granted
Mar 18, 2025
Kind
B2
Abstract

Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH 2 .

Claims (12)

1. A crystalline form of a tosylate salt of Compound I,

wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 11.6, 12.2, 13.4, 15.4, 17.0, 20.2, 22.4, 22.7, and 23.1.

2. The crystalline form of claim 1 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 6.3, 11.6, 12.2, 13.4, 14.7, 15.4, 16.1, 17.0, 18.9, 20.2, 22.4, 22.7, and 23.1.

3. A crystalline form of a tosylate salt of Compound I,

wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 6.5, 12.0, 13.0, 13.3, 15.7, 17.3, 19.4, 20.5, and 23.1.

4. The crystalline form of claim 3 , wherein said crystalline form has characteristic peaks in its XRPD pattern at values of two theta (° 2θ) of: 6.5, 11.6, 11.8, 12.0, 13.0, 13.3, 15.0, 15.7, 15.9, 17.3, 19.4, 19.6, 20.5, 22.4, 22.8, 23.1, and 23.7.

5. A composition, comprising a crystalline form of claim 1 .

6. A process for making a pharmaceutical composition comprising Compound I,

comprising dissolving a crystalline form of claim 1 .

7. A composition, comprising a crystalline form of claim 3 .

8. A process for making a pharmaceutical composition comprising Compound I,

comprising dissolving a crystalline form of claim 3 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2023
From: DUNCAN, SCOTT M.; REDMON, MARTIN P.
To: STEALTH BIOTHERAPEUTICS CORP.
Reel/Frame 064110/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2023
From: STEALTH BIOTHERAPEUTICS CORP.
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 064163/0320 →
Continuity (4)
Continuation 16866164 · May 4, 2020
Continuation 16084168
Provisional Application 62307095 · Mar 11, 2016
Related Publication 20230279049A1 · Sep 7, 2023
References Cited (51)
US 5312899A · Schiller · 1994 [cited by applicant]
US 9549963B2 · Liu et al. · 2017 [cited by applicant]
US 9982014B2 · Hirai et al. · 2018 [cited by applicant]
US 10676506B2 · Duncan · 2020 [cited by applicant]
US 10683326B2 · Duncan et al. · 2020 [cited by applicant]
US 10961273B2 · Duncan et al. · 2021 [cited by applicant]
US 10975118B2 · Duncan et al. · 2021 [cited by applicant]
US 11034724B2 · Duncan · 2021 [cited by applicant]
US 11261213B2 · Duncan · 2022 [cited by applicant]
US 11555053B2 · Duncan et al. · 2023 [cited by applicant]
US 11773136B2 · Duncan · 2023 [cited by applicant]
US 20110177047A1 · Liu et al. · 2011 [cited by applicant]
US 20120178762A1 · Redman-Furey et al. · 2012 [cited by applicant]
US 20120329730A1 · Szeto et al. · 2012 [cited by applicant]
US 20130059784A1 · Wilson · 2013 [cited by applicant]
US 20140044689A1 · Liu et al. · 2014 [cited by applicant]
US 20150359838A1 · Szeto et al. · 2015 [cited by applicant]
US 20160264623A1 · Hirai et al. · 2016 [cited by applicant]
US 20180044378A1 · Duncan et al. · 2018 [cited by applicant]
US 20190202861A1 · Duncan et al. · 2019 [cited by applicant]
US 20190233474A1 · Duncan · 2019 [cited by applicant]
US 20190382442A1 · Duncan et al. · 2019 [cited by applicant]
US 20200283476A1 · Duncan et al. · 2020 [cited by applicant]
US 20200308221A1 · Duncan et al. · 2020 [cited by applicant]
US 20200369724A1 · Duncan · 2020 [cited by applicant]
US 20210047368A1 · Duncan et al. · 2021 [cited by applicant]
US 20210061853A1 · Duncan · 2021 [cited by applicant]
US 20210292362A1 · Duncan · 2021 [cited by applicant]
US 20240140990A1 · Duncan · 2024 [cited by applicant]
CN 102428086A · 2012 [cited by applicant]
CN 103003283A · 2013 [cited by applicant]
CN 104244964A · 2014 [cited by applicant]
WO WO2010125004A1 · 2010 [cited by applicant]
WO WO2011156473A1 · 2011 [cited by applicant]
WO WO2013126597A1 · 2013 [cited by applicant]
WO WO2014134562A1 · 2014 [cited by examiner]
WO WO2015084649A1 · 2015 [cited by applicant]
WO WO2016001042A1 · 2016 [cited by applicant]
WO WO2016007921A1 · 2016 [cited by applicant]
Bauer, “Pharmaceutical solids-the amorphous phase,” Journal of Validation Technology 15.3 (2009): 63-68. [cited by applicant]
Brittain, “Polymorphism in pharmaceutical solids,” Drugs and the Pharmaceutical Sciences, 192 (2009): 76-138. [cited by applicant]
Gupta et al., “Salts of therapeutic agents: chemical, physicochemical, and biological considerations,” Molecules 23.7 (2018): 1719, 1-15. [cited by applicant]
Carpino et al., “Rapid, continuous solution phase synthesis: application to peptides of pharmaceutical interest,” Organic Process Research and Development, 7: 28-37 (2003). [cited by applicant]
Dai et al., “Mitochondrial Targeted Antioxidant Peptide Ameliorates Hypertensive Cardiomyopathy,” J Am Coll Cardiol, 58(1): 73-82 (2011). [cited by applicant]
Dolca et al., “Mitochondrial targeting with antioxidant peptide ss-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function,” Journal … [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US17/21790 dated Jun. 5, 2017. [cited by applicant]
Palladino et al., “New TFA-Free Cleavage and Final Deprotection in Fmoc Solid-Phase Peptide Synthesis: Dilute HCI in Fluoro Alcohol” Org. Lett. 14(24): 6346-6349 (2012). [cited by applicant]
Peng et al., “Site-specific chemical modifications of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag,” Proceedings of the National Academy of Sciences of the United States… [cited by applicant]
Sabbah et al., “Chronic Therapy with Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs with Advanced Heart Failure,” Circ Heart Fail, 9(2): 1-10… [cited by applicant]
Sabbah et al., “Long-term therapy with Bendavia (MTP-131), a novel mitochondria-targeting peptide, normalizes functional mitochondrial abnormalities in left ventricular myocardium of dogs with heart failure,” Mitochondr… [cited by applicant]
Yang et al., “Role of mitochondria in the pathogenesis and treatment of glaucoma,” National Medical Journal of China (English), 22: 4358-4365 (2013). [cited by applicant]